Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML.
Brian J Ball, Wenbin Xiao, Gautam Borthakur...
https://pubmed.ncbi.nlm.nih.gov/40665325/Actively Recruiting
Led by Edgewood Oncology Inc. · Updated on 2025-01-30
112
Participants Needed
6
Research Sites
52 weeks
Total Duration
Researchers are evaluating the safety, toxicity, and pharmacokinetics of BTX-A51, alone and combined with fulvestrant, in people with advanced solid tumors and metastatic breast cancer that is estrogen receptor positive and HER2 negative. This phase 1, open-label study aims to find the safe dose levels and observe preliminary effects of the treatments in this patient group. The study includes multiple phases to carefully assess dosing and safety. The study has three phases. Phase 1a is a dose escalation phase where BTX-A51 is taken orally once daily on a schedule of 5 days on and 2 days off, in 28-day cycles. Dose levels increase sequentially to find the maximum tolerated dose. Phase 1b involves dose ranging of BTX-A51 alone in patients with specific breast cancer mutations, with dosing over 28 days. Phase 1c tests BTX-A51 combined with fulvestrant, an injection given on specific days within 28-day cycles, to evaluate combined safety. Participants will take BTX-A51 orally and may receive fulvestrant by injection if in the combination phase. Researchers will monitor adverse events, dose tolerance, and drug levels in the blood, collecting blood samples at specific times during treatment cycles. They will also assess response rates, duration of response, progression-free survival, and overall survival for up to two years after treatment. Safety follow-up continues for 30 days post-treatment, with options for continued access to BTX-A51 until disease progression or unacceptable toxicity.
CONDITIONS
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Z
Zung Thai, MD
E
Edgar Bautista, BS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Edgewood Oncology Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | BTX-A51 (alone or with fulvestrant) | Guideline-recommended systemic therapy |
|---|---|---|
| What it is | BTX-A51 is an oral investigational inhibitor of casein kinase 1 alpha and cyclin dependent kinases 7/9, given alone or in combination with fulvestrant, evaluated in adults with treatment-refractory advanced solid tumors or metastatic ER-positive, HER2-negative breast cancer. | Guideline-recommended systemic therapy includes cytotoxic chemotherapy, endocrine therapy, or palliative/supportive care for patients with advanced solid tumors or metastatic breast cancer who have progressed on or are intolerant to all standard options. |
| Role in trial | Investigational therapy administered alone (dose escalation/expansion) or in combination with fulvestrant, as the sole intervention under investigation in each corresponding trial cohort. | Represents established guideline-based management options typically offered to patients who have advanced solid tumors or metastatic breast cancer unresponsive to standard therapies. |
| Primary use or purpose | Being assessed for safety and definition of maximum tolerated dose, alone or with fulvestrant, in participants with advanced/metastatic tumors after standard therapy failure or intolerance. | Aims to provide disease control and symptom palliation when cure is not feasible, and to individualize therapy based on patient preference, prior response, and comorbidities. |
| How it is given or performed | Oral BTX-A51 is administered daily up to 5 days per week in 28-day cycles as monotherapy or combined with fulvestrant, with dose escalation and expansion cohorts determining tolerated doses. | Systemic therapy options can include intravenous or oral chemotherapy, oral endocrine agents, or best supportive care. Selection and regimen depend on prior treatments, comorbidities, and patient preferences. |
| Evidence status | Safety, tolerability, and preliminary efficacy of BTX-A51 are still being investigated; no published efficacy or outcome data for solid tumors or metastatic breast cancer are established yet. | Post-standard systemic therapies and endocrine agents have limited efficacy in this population; median progression-free survival and response rates are generally low, but benefits can occur in select cases. |
| Important limitations | The safety, tolerability, and effect on disease outcomes of BTX-A51 in solid tumors and metastatic breast cancer are not yet established. Only early-phase, non-randomized dose-finding cohorts are available with limited evidence specific to these patient populations. | Systemic therapies for advanced solid tumors or metastatic breast cancer after failure of standard treatments offer limited likelihood of response; side effects and declining performance status may further restrict use. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
screening and enrollment visit
Duration - One 28-day cycle of treatment; participants may continue until disease progression or unacceptable toxicity.
Participants receive BTX-A51 with a weekly dosing schedule of up to 5 days per week in 28-day cycles, alone or in combination with fulvestrant. Fulvestrant is administered as intramuscular injections on specific days during the cycles.
Weekly visits for up to 4 weeks (one cycle) with dosing 3 to 5 times per week depending on cohort
Duration - Up to 2 years after the last treatment or upon death
Participants are monitored for safety and treatment effects for up to 2 years after the last treatment or until death.
Periodic visits during follow-up period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
8
Have more questions? Get in touch with our team for quick support
Brian J Ball, Wenbin Xiao, Gautam Borthakur...
https://pubmed.ncbi.nlm.nih.gov/40665325/Edgewood Oncology Inc.
Lead Sponsor